Published in:
01-10-2015 | Original Article
Absorption, distribution, metabolism, and excretion of [14C]BYL719 (alpelisib) in healthy male volunteers
Authors:
Alexander James, Lars Blumenstein, Ulrike Glaenzel, Yi Jin, Arnold Demailly, Annamaria Jakab, Regine Hansen, Katharine Hazell, Anuradha Mehta, Lucia Trandafir, Piet Swart
Published in:
Cancer Chemotherapy and Pharmacology
|
Issue 4/2015
Login to get access
Abstract
Purpose
To determine the pharmacokinetics of the p110α-selective inhibitor alpelisib (BYL719) in humans, to identify metabolites in plasma and excreta, and to characterize pathways of biotransformation.
Methods
Four healthy male volunteers received a single oral dose of [14C]-labeled alpelisib (400 mg, 2.78 MBq). Blood, urine, and feces samples were collected throughout the study. Total radioactivity was measured by liquid scintillation counting, and metabolites were quantified and identified by radiometry and mass spectrometry. Complementary in vitro experiments characterized the hydrolytic, oxidative, and conjugative enzymes involved in metabolite formation.
Results
Over 50 % of [14C] alpelisib was absorbed, with a T
max of 2 h and an elimination half-life from plasma of 13.7 h. Over the first 12 h, exposure to alpelisib and the primary metabolite M4 was 67.9 and 26.7 % of total drug-related material in circulation, respectively. Mass balance was achieved, with 94.5 % of administered radioactivity recovered in excreta. In total, 38.2 % of alpelisib was excreted unchanged, while 39.5 % was excreted as M4. Based on the excreta pools analyzed, excretion occurred mainly via feces (79.8 % of administered dose); 13.1 % was excreted via urine. In vitro experiments showed that spontaneous and enzymatic hydrolysis contributed to M4 formation, while CYP3A4-mediated oxidation and UGT1A9-mediated glucuronidation formed minor metabolites. Alpelisib was well tolerated, and no new safety concerns were raised during this study.
Conclusions
Alpelisib was rapidly absorbed and cleared by multiple metabolic pathways; the primary metabolite M4 is pharmacologically inactive. Alpelisib has limited potential for drug–drug interactions and is therefore a promising candidate for combination therapy.